Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis

Overview

Journal J Oncol

Specialty Oncology

Date 2020 Apr 8

PMID 32256580

Citations 39

Authors

Vladimir Jurisic

Vladimir Vukovic

Jasmina Obradovic

Lyudmila F Gulyaeva

Nikolay E Kushlinskii

Natasa Djordjevic

Affiliations

Soon will be listed here.

Abstract

Tyrosine kinase inhibitor- (TKI-) based therapy revolutionized the overall survival and the quality of life in non-small-cell lung cancer (NSCLC) patients that have epidermal growth factor receptor () mutations. However, is a highly polymorphic and mutation-prone gene, with over 1200 single nucleotide polymorphisms (SNPs). Since the role of polymorphism on the treatment outcome is still a matter of debate, this research analyzed the available literature data, according to the PRISMA guidelines for meta-analyses. Research includes PubMed, Scopus, ISI Web of Science, and 14 of genome-wide association studies (GWAS) electronic databases in order to provide quantitative assessment of the association between ten investigated SNPs and the survival of NSCLC patients. The pooled HR and their 95% CI for OS and PFS for different polymorphisms using a random or fixed effect model based on the calculated heterogeneity between the studies was applied. The longest and the shortest median OSs were reported for the homozygous wild genotype and a variant allele carriers for rs712829 (-216G>T), respectively. Quantitative synthesis in our study shows that out of ten investigated SNPs (rs11543848, rs11568315, rs11977388, rs2075102, rs2227983, rs2293347, rs4947492, rs712829, rs712830, and rs7809028), only four, namely, rs712829 (-216G>T), rs11568315 (CA repeat), rs2293347 (D994D), and rs4947492, have been reported to affect the outcome of TKI-based NSCLC treatment. Of these, only -216G>T and variable CA repeat polymorphisms have been confirmed by meta-analysis of available data to significantly affect OS and PFS in gefitinib- or erlotinib-treated NSCLC patients.

Citing Articles

Meta-analysis of gene polymorphisms and lung cancer risk.

Fakhkhari M, Salih I, Errafii K, Hamdi S, Sadki K Int J Immunopathol Pharmacol. 2025; 39:3946320251316731.

PMID: 39936564 PMC: 11822845. DOI: 10.1177/03946320251316731.

Construction of a lung adenocarcinoma prognostic model based on KEAP1/NRF2/HO‑1 mutation‑mediated upregulated genes and bioinformatic analysis.

Zhu W, Zhang Y, Yang L, Chen L, Chen C, Shi Q Oncol Lett. 2025; 29(3):155.

PMID: 39911153 PMC: 11795234. DOI: 10.3892/ol.2025.14902.

Identification of Prognosis Signature Based on cGAS-STING Pathway and Its Immunotherapeutic Significance in Lung Adenocarcinoma.

Huang X, Lv X, Cao X Mol Biotechnol. 2025; .

PMID: 39890699 DOI: 10.1007/s12033-025-01376-x.

Evaluation of the efficacy of PD‑1/PD‑L1 inhibitor plus bevacizumab and chemotherapy for the treatment of patients with driver gene‑negative advanced‑stage lung adenocarcinoma: A retrospective cohort study.

Yang X, Li X, Huang K, Zhuang X Oncol Lett. 2024; 29(1):53.

PMID: 39584040 PMC: 11582526. DOI: 10.3892/ol.2024.14799.

N6-Methyladenosine Modification of PERP by RBM15 Enhances the Tumorigenesis of Lung Adenocarcinoma via p53 Signaling Pathway.

Li R, Xia X, Chen W, Wang H, Feng L, Wang Z Mol Biotechnol. 2024; .

PMID: 39556280 DOI: 10.1007/s12033-024-01323-2.

References

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

Zhang X, Fan J, Li Y, Lin S, Shu P, Ni J . Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Tumour Biol. 2015; 37(1):1061-9. DOI: 10.1007/s13277-015-3893-1. View

Johnson A, Ishii S, Jinno Y, Pastan I, Merlino G . Epidermal growth factor receptor gene promoter. Deletion analysis and identification of nuclear protein binding sites. J Biol Chem. 1988; 263(12):5693-9. View

Maekawa T, Imamoto F, Merlino G, Pastan I, Ishii S . Cooperative function of two separate enhancers of the human epidermal growth factor receptor proto-oncogene. J Biol Chem. 1989; 264(10):5488-94. View

Liu W, Innocenti F, Chen P, Das S, Cook Jr E, Ratain M . Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res. 2003; 9(3):1009-12. View

Liu G, Gurubhagavatula S, Zhou W, Wang Z, Yeap B, Asomaning K . Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J. 2007; 8(2):129-38. DOI: 10.1038/sj.tpj.6500444. View

Dubey S, Stephenson P, Levy D, Miller J, Keller S, Schiller J . EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol. 2007; 1(5):406-12. View

Jung M, Cho B, Lee C, Park H, Kang Y, Kim S . EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. Yonsei Med J. 2012; 53(6):1128-35. PMC: 3481391. DOI: 10.3349/ymj.2012.53.6.1128. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

10.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

11.

Arora A, Scholar E . Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005; 315(3):971-9. DOI: 10.1124/jpet.105.084145. View

12.

Ioannidis J, Trikalinos T . The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ. 2007; 176(8):1091-6. PMC: 1839799. DOI: 10.1503/cmaj.060410. View

13.

Luo S, Lam D . Oncogenic driver mutations in lung cancer. Transl Respir Med. 2016; 1(1):6. PMC: 6733434. DOI: 10.1186/2213-0802-1-6. View

14.

Takeda M, Nakagawa K . First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive Mutation-Positive Non-Small Cell Lung Cancer?. Int J Mol Sci. 2019; 20(1). PMC: 6337322. DOI: 10.3390/ijms20010146. View

15.

Nie Q, Yang X, An S, Zhang X, Yang J, Zhong W . CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism. Eur J Cancer. 2011; 47(13):1962-70. DOI: 10.1016/j.ejca.2011.04.018. View

16.

Cubillos-Angulo J, Fukutani E, Cruz L, Arriaga M, Lima J, Andrade B . Systems biology analysis of publicly available transcriptomic data reveals a critical link between AKR1B10 gene expression, smoking and occurrence of lung cancer. PLoS One. 2020; 15(2):e0222552. PMC: 7041805. DOI: 10.1371/journal.pone.0222552. View

17.

Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K . Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019; 11:943-953. PMC: 6345192. DOI: 10.2147/CMAR.S187317. View

18.

Kimchi-Sarfaty C, Oh J, Kim I, Sauna Z, Calcagno A, Ambudkar S . A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2006; 315(5811):525-8. DOI: 10.1126/science.1135308. View

19.

Jurisic V, Obradovic J, Pavlovic S, Djordjevic N . Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation. Anal Cell Pathol (Amst). 2018; 2018:6192187. PMC: 6204164. DOI: 10.1155/2018/6192187. View

20.

Juan O, Popat S . Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Ther Adv Med Oncol. 2017; 9(3):201-216. PMC: 5349427. DOI: 10.1177/1758834016687262. View